29482-57-3

Upstream product

• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 32631-26-8 4-amino-2-chlorophenyl phenyl sulphide 
• 108-98-5 thiophenol 

Downstream Products

• 32631-26-8 4-amino-2-chlorophenyl phenyl sulphide 
• 1289212-93-6 C₁₄H₁₀ClNO₃S 
• 1620782-74-2 N³-(3-chloro-4-(phenylthio)phenyl)-N₃-methyl-1H-1,2,4-triazole-3,5-diamine 
• 1620782-73-1 N³-(3-chloro-4-(phenylsulfonyl)phenyl)-1H-1,2,4-triazole-3,5-diamine 
• 1620878-62-7 (Z)-methyl N-3-chloro-4-(phenylsulfonyl)phenyl-N'-cyanocarbamimidothioate 
• 1620783-08-5 2-chloro-4-isothiocyanato-1-(phenylsulfonyl)benzene 
• 32631-31-5 1-amino-3-chloro-4-phenylsulfonylbenzene 
• 1620782-72-0 N³-(3-chloro-4-(phenylthio)phenyl)-1H-1,2,4-triazole-3,5-diamine 
• 1620878-61-6 (Z)-methyl N-3-chloro-4-(phenylthio)phenyl-N'-cyanocarbamimidothioate 
• 1620783-07-4 (2-chloro-4-isothiocyanatophenyl)(phenyl)sulfane 

Relevant academic research and scientific papers

ANTIVIRAL TRIAZOLE DERIVATIVES

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

Modulation of cAMP-specific PDE without emetogenic activity: New sulfide-like PDE7 inhibitors

A forward chemical genetic approach was followed to discover new targets and lead compounds for Parkinson's disease (PD) treatment. By analysis of the cell protection produced by some small molecules, a diphenyl sulfide compound was revealed to be a new phosphodiesterase 7 (PDE7) inhibitor and identified as a new hit. This result allows us to confirm the utility of PDE7 inhibitors as a potential pharmacological treatment of PD. On the basis of these data, a diverse family of diphenyl sulfides has been developed and pharmacologically evaluated in the present work. Moreover, to gain insight into the safety of PDE7 inhibitors for human chronic treatment, we evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.

The synthesis and SAR of novel diarylsulfone 11β-HSD1 inhibitors

In this communication, human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitory activities of a novel series of diarylsulfones are described. Optimization of this series resulted in several highly potent 11β-HSD1 inhibitors with excellent pharmacokinetic (PK) properties. Compound (S)-25 showed excellent efficacy in a non-human primate ex vivo pharmacodynamic model.

Aniline derivatives

The invention concerns aniline derivatives of formula I STR1 wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R1 and R2 are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.

Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase

Six new diphenyl sulfoxide and five new diphenyl sulfones were designed, synthesized, and tested for their inhibition of human and Escherichia coli thymidylate synthase (TS) and of the growth of cells in tissue culture. The best sulfoxide inhibitor of hum